Electric Tumor Treating Fields (Optune)

This policy covers electric tumor‑treating fields (TTF) therapy (Optune/Optune Gio) for treatment of supratentorial glioblastoma in adults, including initial 90‑day TTF with temozolomide for newly diagnosed GBM and TTF monotherapy for recurrent GBM. Coverage is limited to patients aged ≥22 years with Karnofsky Performance Status ≥60 who agree to wear the device ≥18 hours/day under physician supervision (initial and continuation authorizations, with 90‑day extensions if no progression); exclusions include implanted electrical devices, skull defects, pregnancy, use as a substitute for standard therapies, and other non‑GBM indications, and the evidence base has notable limitations.

"Treatment of glioblastoma using tumor treating fields (TTF) therapy (device example: Optune Gio) in adults aged ≥22 years"

Sign up to see full coverage criteria, indications, and limitations.